On Wednesday, Ameriprise Financial, Inc. (NYSE:AMP)’s shares declined -0.53% to $106.92.
For the fifth year in a row, Ameriprise Financial is matching public donations to Feeding America®–up to$500,000– in support of Hunger Action MonthTM. As part of the Ameriprise Financial Challenge, individuals can double the impact of their gift to Feeding America, the nation’s leading domestic hunger-relief organization, ahead of the busy holiday season.* When combined with the Ameriprise gift, every dollar donated now through Thanksgiving can have twice the impact. That means together we can assist provide 11 million meals to families facing hunger in the U.S. through the Feeding America network of food banks.
Ameriprise began a charitable partnership with Feeding America in 2009 with the aim to assist meet an raised demand on food banks and work toward finding long-term solutions to domestic hunger. Together with its advisors, employees and volunteers, Ameriprise has offered more than 40 million meals and volunteered more than 130,000 hours to support hunger-relief organizations nationwide.
Ameriprise Financial, Inc., through its auxiliaries, provides various financial products and services to individual and institutional clients in the United States and internationally. The company’s Advice & Wealth Administration segment provides financial planning and advice, in addition to full-service brokerage services primarily to retail clients through its advisors. Its Asset Administration segment offers investment advice and investment products to retail, high net worth, and institutional clients through unassociated third party financial institutions and institutional sales force.
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)’s shares gained 23.14% to $22.46.
Concert Pharmaceuticals, Inc. (CNCE) declared positive data from a Phase 1 single ascending dose clinical trial of CTP-656. CTP-656 is a novel deuterium-modified version of ivacaftor, which is commercially accessible as a single agent under the name Kalydeco® and as part of a fixed-dose combination therapy called Orkambi®. The clinical results continue to support the development of CTP-656 as a once daily potentiator for the treatment of certain cystic fibrosis genotypes as monotherapy or in combination with other CFTR modulators. CTP-656 demonstrated a superior pharmacokinetic profile contrast to Kalydeco, current standard of care. Results of the Phase 1 trial also showed that CTP-656 was well-tolerated and its safety profile was comparable to Kalydeco. The Phase 1 single dose results were presented during the “hot off the press” session at the Cystic Fibrosis Trusts UK Conference 2015 in Manchester, England.
The Phase 1 clinical trial was designed to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of CTP-656 in addition to to provide a comparison with a single dose of Kalydeco in ten healthy volunteers. Three doses (75, 150 and 300 mg) of CTP-656 were administered as an aqueous suspension. Additionally, a 150 mg dose of CTP-656 was contrast to a 150 mg solid dose of Kalydeco in nine subjects. CTP-656 was well-tolerated across all dose groups. There were no serious adverse events stated in subjects who received CTP-656.
Concert Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drugs for central nervous system disorders, genetic diseases, renal disease, inflammatory disease, and cancer.
At the end of Wednesday’s trade, salesforce.com, inc. (NYSE:CRM)‘s shares dipped -0.01% to $71.98.
Salesforce (CRM), the Customer Success Platform and world’s #1 CRM company, declared Salesforce IoT Cloud. Powered by Thunder, a massively scalable, real-time event processing engine, IoT Cloud connects billions of events with Salesforce, unlocking insights from the connected world that empower anyone to take the right action, for the right customer, at the right time.
Connected World, Disconnected Data
The combination of mobile, social, sensor, wearable and cloud technologies has triggered a deluge of data. More than 90 percent of the world’s data has been generated over the last two years.1 And, with the number of connected devices projected to reach 75 billion by 2020,2 the volume of data accessible is predictable to grow exponentially.
This world of connected devices and digital content presents an enormous opportunity for companies to take advantage of the new data. In a June 2015 report, the McKinsey Global Institute estimates that IoT applications may have a potential economic impact of as much as $11.1 trillion per year by 2025.3 However, businesses have been unable to capitalize on the vast volume of data from the Internet of Things.
salesforce.com, inc. provides enterprise cloud computing solutions, with a focus on customer relationship administration to various businesses and industries worldwide. The company offers enterprise cloud computing apps and platform services, counting Sales Cloud for sales force automation, which enables companies to store data, access accurate customer and prospect information, track leads and progress, forecast opportunities, and collaborate around any sale on desktop and mobile devices; Service Cloud that enables companies to connect address customers service and support needs; and Marketing Cloud, which enables companies to map customer journeys to digital marketing interactions through email, mobile, social, Web, and connected products.
EXCO Resources Inc(NYSE:XCO), ended its Wednesday’s trading session with 1.07% gain, and closed at $0.853.
EXCO Resources, Inc. (XCO) declares the closing under the Services and Investment Agreement with Energy Planned Advisory Services LLC (“ESAS”), a wholly owned partner of Bluescape Resources Company LLC (“Bluescape”). Highlights comprise:
- John Wilder, Executive Chairman of Bluescape Resources Company LLC, has joined EXCO’s Board of Directors and been designated EXCO’s Executive Chairman.
- John Wilder and ESAS will continue to lead EXCO’s transformational strategy that focuses on six core areas: 1) liability administration, 2) operational performance, 3) capital deployment, 4) risk administration, 5) portfolio repositioning, and 6) performance administration.
- ESAS has purchased from EXCO 5,882,353 shares of EXCO’s common stock for a purchase price of $10 million at $1.70 per share (the ten day volume weighted average price of EXCO’s common stock as of March 30, 2015).
EXCO Resources, Inc., an independent oil and natural gas company, engages in the acquisition, exploration, exploitation, development, and production of onshore oil and natural gas properties with a focus on shale resource plays in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
